PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.094|
|52 Week High||AU$0.081|
|52 Week Low||AU$0.14|
|1 Month Change||4.44%|
|3 Month Change||0%|
|1 Year Change||-35.17%|
|3 Year Change||100.00%|
|5 Year Change||14.64%|
|Change since IPO||-98.96%|
Recent News & Updates
This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid
Shareholders will be pleased by the impressive results for PharmAust Limited ( ASX:PAA ) recently and CEO Roger Aston...
|PAA||AU Pharmaceuticals||AU Market|
Return vs Industry: PAA underperformed the Australian Pharmaceuticals industry which returned -2.5% over the past year.
Return vs Market: PAA underperformed the Australian Market which returned 19.3% over the past year.
Stable Share Price: PAA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PAA's weekly volatility (6%) has been stable over the past year.
About the Company
PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer.
PharmAust Fundamentals Summary
|PAA fundamental statistics|
Is PAA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAA income statement (TTM)|
|Cost of Revenue||AU$225.32k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0042|
|Net Profit Margin||-36.57%|
How did PAA perform over the long term?See historical performance and comparison
Is PharmAust undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PAA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PAA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PAA is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: PAA is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PAA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PAA's PB Ratio (3.4x) is in line with the AU Pharmaceuticals industry average.
How is PharmAust forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PharmAust has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has PharmAust performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAA is currently unprofitable.
Growing Profit Margin: PAA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAA is unprofitable, but has reduced losses over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare PAA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.1%).
Return on Equity
High ROE: PAA has a negative Return on Equity (-15.06%), as it is currently unprofitable.
How is PharmAust's financial position?
Financial Position Analysis
Short Term Liabilities: PAA's short term assets (A$4.4M) exceed its short term liabilities (A$911.4K).
Long Term Liabilities: PAA's short term assets (A$4.4M) exceed its long term liabilities (A$1.2M).
Debt to Equity History and Analysis
Debt Level: PAA's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: PAA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PAA has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 14.3% each year.
What is PharmAust current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PAA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Aston (65 yo)
Dr. Roger Aston, B.Sc. (Hons), Ph D., has been Acting Chief Executive Officer of PharmAust Ltd since May 25, 2018. Dr. Aston serves as the Chief Executive Officer at Pitney Pharmaceuticals Pty Ltd.Dr. Ast...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD211.12K) is about average for companies of similar size in the Australian market ($USD300.24K).
Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.
Experienced Management: PAA's management team is considered experienced (3.4 years average tenure).
Experienced Board: PAA's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PAA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PharmAust Limited's employee growth, exchange listings and data sources
- Name: PharmAust Limited
- Ticker: PAA
- Exchange: ASX
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$29.790m
- Shares outstanding: 316.91m
- Website: https://www.pharmaust.com
- PharmAust Limited
- 5/3 Brodie Hall Drive
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 15:41|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.